Sanofi US
NEWS
Read on to learn more about three Series B and C financing rounds in the areas of genetically encoded small molecules, artificial intelligence (AI) and immuno-oncology (IO).
Healthcare giant Sanofi and cancer-focused biotech company Seagen Inc. announced an exclusive collaboration agreement to develop antibody-drug conjugates (ADCs) for cancer treatments.
Cambridge Crossing will enable innovative drug discovery platforms for chemistry, protein engineering, structural and synthetic biology, among other key modalities.
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
In the Phase III MELODY trial, researchers found a 74.5% lower incidence of respiratory syncytial virus-caused pneumonia, and bronchiolitis. Here’s more about it.
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
In 2021, Sanofi earned about $4.2 billion from Dupixent sales, and Regeneron earned about $1.8 billion.
Clinical Catch-Up for February 21
JOBS
IN THE PRESS